67 related articles for article (PubMed ID: 32221861)
1. Changes in Anti-JCV Antibody Status in a Large Population of Multiple Sclerosis Patients Treated with Natalizumab.
Sgarlata E; Chisari CG; D'Amico E; Millefiorini E; Patti F
CNS Drugs; 2020 May; 34(5):535-543. PubMed ID: 32221861
[TBL] [Abstract][Full Text] [Related]
2. Switching from natalizumab to an anti-CD20 monoclonal antibody in relapsing remitting multiple sclerosis: A systematic review.
Brown JD; Muston BT; Massey J
Mult Scler Relat Disord; 2024 Jun; 86():105605. PubMed ID: 38640586
[TBL] [Abstract][Full Text] [Related]
3. Design of TRUST, a non-interventional, multicenter, 3-year prospective study investigating an integrated patient management approach in patients with relapsing-remitting multiple sclerosis treated with natalizumab.
Ziemssen T; Gass A; Wuerfel J; Bayas A; Tackenberg B; Limmroth V; Linker R; Mäurer M; Haas J; Stangel M; Meergans M; Harlin O; Hartung HP
BMC Neurol; 2016 Jul; 16():98. PubMed ID: 27405225
[TBL] [Abstract][Full Text] [Related]
4. Association of B-cell activating factor gene variants with serum anti-JCV antibody positivity in male patients with multiple sclerosis under natalizumab treatment: Implications for progressive multifocal leukoencephalopathy risk stratification.
Skarlis C; Papadopoulos V; Raftopoulou S; Mavragani CP; Evangelopoulos ME
J Neurol Sci; 2024 May; 461():123046. PubMed ID: 38761670
[TBL] [Abstract][Full Text] [Related]
5. Evidence of disease activity during pregnancy and post-partum in MS patients treated with high-efficacy therapies.
Sahloul O; Louapre C; Beigneux Y; Lubetzki C; Maillart E; Roux T
Mult Scler Relat Disord; 2024 May; 85():105557. PubMed ID: 38520946
[TBL] [Abstract][Full Text] [Related]
6. Safety and efficacy of extended versus standard interval dosing of natalizumab in multiple sclerosis patients: a systematic review and meta-analysis.
Rabea EM; Belal MM; Hafez AH; Elbanna AH; Khalifa MA; Nourelden AZ; Mahmoud NH; Zaazouee MS
Acta Neurol Belg; 2024 Apr; 124(2):407-417. PubMed ID: 38457005
[TBL] [Abstract][Full Text] [Related]
7. The impact of social distancing measures on anti-JC virus serostatus changes before and during the COVID-19 pandemic in US patients with multiple sclerosis.
Krieger SC; Sinks S; Huang F; Steverson J; Kalina TJ; White K; Avila RL
Mult Scler; 2024 Jun; 30(7):888-892. PubMed ID: 38406828
[TBL] [Abstract][Full Text] [Related]
8. Absence of JC polyomavirus in stool samples of patients with multiple sclerosis despite high anti-JCV antibodies in serum.
Schweitzer F; Ladwig A; Opala S; Laurent S; Schroeter M; Goelz S; Fink GR; Wieland U; Silling S; Warnke C
Mult Scler Relat Disord; 2024 May; 87():105664. PubMed ID: 38735204
[TBL] [Abstract][Full Text] [Related]
9. Risk of secondary progression in patients with highly active multiple sclerosis treated with natalizumab: a real-life study.
Scherer L; Soudant M; Pittion-Vouyovitch S; Debouverie M; Guillemin F; Epstein J; Mathey G
J Neurol; 2024 May; 271(5):2216-2224. PubMed ID: 38421420
[TBL] [Abstract][Full Text] [Related]
10. JC Virus Seroprevalence and JCVAb Index in Polish Multiple Sclerosis Patients Treated with Immunomodulating or Immunosuppressive Therapies.
Bonek R; Guenter W; Jałowiński R; Karbicka A; Litwin A; Maciejowski M; Zajdel R; Zajdel K; Petit V; Rejdak K
J Clin Med; 2021 May; 10(9):. PubMed ID: 34066624
[TBL] [Abstract][Full Text] [Related]
11. Vaccine Safety and Immunogenicity in Patients With Multiple Sclerosis Treated With Natalizumab.
Carvajal R; Zabalza A; Carbonell-Mirabent P; Martínez-Gómez X; Esperalba J; Pappolla A; Rando A; Cobo-Calvo A; Tur C; Rodriguez M; Río J; Comabella M; Castilló J; Rodrigo-Pendás JÁ; Braga N; Mongay-Ochoa N; Guío-Sánchez C; Vidal-Jordana Á; Arrambide G; Rodríguez-Acevedo B; Midaglia L; Borras-Bermejo B; Galán I; Sastre-Garriga J; Montalban X; Otero-Romero S; Tintoré M
JAMA Netw Open; 2024 Apr; 7(4):e246345. PubMed ID: 38607624
[TBL] [Abstract][Full Text] [Related]
12. Infusion-related events during natalizumab: No need for post-infusion monitoring.
Loonstra FC; van Rossum JA; van Kempen ZL; Rispens T; Uitdehaag BM; Killestein J
Mult Scler; 2020 Oct; 26(12):1590-1593. PubMed ID: 31237826
[TBL] [Abstract][Full Text] [Related]
13. Extending the Interval of Natalizumab Dosing: Is Efficacy Preserved?
Clerico M; De Mercanti SF; Signori A; Iudicello M; Cordioli C; Signoriello E; Lus G; Bonavita S; Lavorgna L; Maniscalco GT; Curti E; Lorefice L; Cocco E; Nociti V; Mirabella M; Baroncini D; Mataluni G; Landi D; Petruzzo M; Lanzillo R; Gandoglia I; Laroni A; Frangiamore R; Sartori A; Cavalla P; Costantini G; Sormani MP; Capra R
Neurotherapeutics; 2020 Jan; 17(1):200-207. PubMed ID: 31452081
[TBL] [Abstract][Full Text] [Related]
14. Long-term effectiveness of natalizumab in secondary progressive multiple sclerosis: A propensity-matched study.
Chisari CG; Aguglia U; Amato MP; Bergamaschi R; Bertolotto A; Bonavita S; Morra VB; Cavalla P; Cocco E; Conte A; Cottone S; De Luca G; Di Sapio A; Filippi M; Gallo A; Gasperini C; Granella F; Lus G; Maimone D; Maniscalco GT; Marfia G; Moiola L; Paolicelli D; Pesci I; Ragonese P; Rovaris M; Salemi G; Solaro C; Totaro R; Trojano M; Vianello M; Zaffaroni M; Lepore V; Patti F;
Neurotherapeutics; 2024 May; ():e00363. PubMed ID: 38714462
[TBL] [Abstract][Full Text] [Related]
15. JC Virus Seroprevalence and JCVAb Index in Polish Multiple Sclerosis Treatment-Naïve Patients.
Bonek R; Guenter W; Jałowiński R; Karbicka A; Litwin A; Maciejowski M; Zajdel R; Petit V; Rejdak K
J Clin Med; 2020 Nov; 9(12):. PubMed ID: 33261210
[TBL] [Abstract][Full Text] [Related]
16. Long-term neuroprotective effects of natalizumab and fingolimod in multiple sclerosis: Evidence from real-world clinical data.
Noteboom S; Strijbis EMM; Coerver EME; Colato E; van Kempen ZLE; Jasperse B; Vrenken H; Killestein J; Schoonheim MM; Steenwijk MD
Mult Scler Relat Disord; 2024 May; 87():105670. PubMed ID: 38772150
[TBL] [Abstract][Full Text] [Related]
17. Natalizumab Treatment of Relapsing Remitting Multiple Sclerosis Has No Long-Term Effects on the Proportion of Circulating Regulatory T Cells.
Tanasescu R; Frakich N; Chou IJ; Filippini P; Podda G; Xin G; Muraleedharan R; Jerca O; Onion D; Constantinescu CS
Neurol Ther; 2023 Dec; 12(6):2041-2052. PubMed ID: 37715885
[TBL] [Abstract][Full Text] [Related]
18. The Effect of Interferon Beta and Natalizumab on miR-20b Expression in Patients with Relapsing-Remitting Multiple Sclerosis is Potentially Mediated by Modulation of the Jak-STAT Signaling Pathway: A Case-control Study.
Jafari Harandi A; Mirzaee Sedigh A; Ataei M; Bayrami S; Esmaeilzadeh E; Sanati MH
Iran J Immunol; 2024 May; 21(2):. PubMed ID: 38761094
[TBL] [Abstract][Full Text] [Related]
19. Non-inferiority analysis of subcutaneous versus intravenous 300 mg monthly natalizumab administration: A post hoc analysis of the REFINE study.
Mealli F; Mattei A; Mariottini A; Massacesi L
Mult Scler; 2024 Mar; ():13524585241238136. PubMed ID: 38481074
[TBL] [Abstract][Full Text] [Related]
20. John Cunningham Virus Status, Seroconversion Rate, and the Risk of Progressive Multifocal Leukoencephalopathy in Polish John Cunningham Virus-Seronegative Patients with Relapsing-Remitting Multiple Sclerosis.
Kapica-Topczewska K; Collin F; Tarasiuk J; Czarnowska A; Chorąży M; Mirończuk A; Kochanowicz J; Kułakowska A
Eur Neurol; 2020; 83(5):487-492. PubMed ID: 33027785
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
